Navigation Links
Unigene's Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
Date:5/22/2012

iencies, our ability to enter into new financing arrangements,  the ability of our products to gain market acceptance and increase market share, the uncertainty of results of animal and human testing, the risk of product liability and liability for human clinical trials, our dependence on patents and other proprietary rights and the risks associated with patent litigation, dependence on key management officials, the availability and cost of capital, the availability of qualified personnel, changes in, or the failure to comply with, governmental regulations, general economic and business conditions, our history of losses and ability to achieve profitability, litigation and other risk factors discussed in our Securities and Exchange Commission ("SEC") filings, including our annual report on Form 10-K and our quarterly reports on Form 10-Q. Words such as "anticipates," "expects," "intends," "plans," "predicts," "believes," "seeks," "estimates," "may," "will," "should," "would," "potential," "continue," and variations of these words (or negatives of these words) or similar expressions, are intended to identify forward-looking statements, but are not the exclusive means of identifying forward-looking statements. In addition, any statements that refer to expectations, projections, contingencies, goals, targets or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements and are not statements of historical fact. Except as required by applicable law, including the securities laws of the United States and the rules and regulations of the SEC, we are under no obligation to publicly update or revise any forward-looking statements after the date of this release.

Investor Contact:
Unigene Laboratories, Inc.
Jenene Thomas
VP, Investor Relations and Business Administration
973-265-1107
jthomas@unigene.com

<
'/>"/>

SOURCE Unigene Laboratories, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. TargeGen Affiliates Scheduled for Oral Presentation of Interim Clinical Trial Data at 2008 ASH Meeting in San Francisco for TG101348, a Potent, Selective, Oral JAK2 Inhibitor in Myeloproliferative Disease Patients
2. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
3. Ceregene Parkinsons Disease Study Demonstrates Long-term Neurturin Expression and Enhanced Dopamine Activity 4 Years Following Delivery of CERE-120 (AAV2-neurturin)
4. AXIOS™ Stent and Delivery System Study Demonstrates Successful Treatment of Pancreatic Pseudocysts and Acute Cholecystitis
5. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
6. OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
7. Soligenix Demonstrates Positive Proof of Concept with its Proprietary Vaccine Thermostabilization Technology
8. Boston Scientific Epic™ Stent Demonstrates Positive Clinical Outcomes in Orion Trial
9. 10-Year Study Demonstrates IRIDEX MicroPulse™ Laser Therapy Safe, Effective for Patients with Diabetic Macular Edema
10. The New England Journal of Medicine Publishes Study Showing LigoCytes Norovirus Vaccine Demonstrates Protection Against Illness
11. Fujifilm Demonstrates the Latest Advancements of Synapse® PACS at RSNA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... April 24, 2015  Lannett Company, Inc. (NYSE: ... increased its five-year revolving credit facility to $120 million ... feature that will allow the company to increase borrowings ... million, subject to securing additional commitments from existing lenders ... credit facility remains December 18, 2018.   ...
(Date:4/24/2015)... Spain , April 24, 2015  Elekta has ... Monaco® treatment planning system , enabling European clinics ... supports major treatment techniques including advanced 3D planning, IMRT, ... system. Monaco ... as well improved workflow efficiency. Advancements in 3D planning ...
(Date:4/23/2015)...  Edwards Lifesciences Corporation (NYSE: EW ), the ... hemodynamic monitoring, today reported net income for the quarter ... diluted share.  Net income for the same period a ... share, and non-GAAP net income was $82.1 million, or ... the quarter ended March 31, 2015 increased 13.0 percent to ...
Breaking Medicine Technology:Lannett Expands Revolving Credit Facility To $120 Million 2Elekta CE marks for Monaco v5.10 treatment planning system 2Edwards Lifesciences Reports First Quarter Results 2Edwards Lifesciences Reports First Quarter Results 3Edwards Lifesciences Reports First Quarter Results 4Edwards Lifesciences Reports First Quarter Results 5Edwards Lifesciences Reports First Quarter Results 6Edwards Lifesciences Reports First Quarter Results 7Edwards Lifesciences Reports First Quarter Results 8Edwards Lifesciences Reports First Quarter Results 9Edwards Lifesciences Reports First Quarter Results 10Edwards Lifesciences Reports First Quarter Results 11Edwards Lifesciences Reports First Quarter Results 12Edwards Lifesciences Reports First Quarter Results 13Edwards Lifesciences Reports First Quarter Results 14Edwards Lifesciences Reports First Quarter Results 15Edwards Lifesciences Reports First Quarter Results 16
... 2 Results from studies related ... ) lead developmental product candidate, fidaxomicin, ... Annual Interscience Conference on Antimicrobial Agents and Chemotherapy ... and Exhibition Center in Boston on September 12-15, ...
... Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins... -- DALLAS, Texas, September 2, 2010 ... ... (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so we need ...
Cached Medicine Technology:Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting 2Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting 3Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies Now Available at ReportsandReports 2Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies Now Available at ReportsandReports 3Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies Now Available at ReportsandReports 4Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies Now Available at ReportsandReports 5Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies Now Available at ReportsandReports 6Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies Now Available at ReportsandReports 7Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies Now Available at ReportsandReports 8
(Date:4/25/2015)... Caicos Islands, BWI (PRWEB) April 25, 2015 ... (PLS) has celebrated three months of successfully welcoming visitors ... January 5, 2015. , As part of a ... of Providenciales airport was completely redesigned to speed up ... up the process of getting out of the airport ...
(Date:4/25/2015)... On Friday, April 17, Interstate Batteries ... Best Implementation Award. This award is given to ... of RFID technology to improve its manufacturing, supply chain ... best demonstrates how RFID is delivering real value to ... Live! 2015 in San Diego, the RFID industries annual ...
(Date:4/24/2015)... As the nation recognizes the Month ... of these young men and women, the “Alaska – ... their Families” presents a special training session on Adverse ... a better understanding of the effect of childhood trauma ... – civilian and military – who provide services and ...
(Date:4/24/2015)... The 1975 have had an intense past two ... theaters, festivals and TV performances. Now that they’ve settled back ... Dirty Hit Records, to provide clean drinking water to those ... Cadence & Cause website, this four-piece has graciously donated ... signed photo card. Entries from this sweepstakes will ...
(Date:4/24/2015)... 2015 Anchor Health Administrators (Anchor), specialists ... today announced their exclusive agreement with LTC Solutions for ... Insurance distribution partner. , Anchor has more than 18 ... benefits for associations, and is currently the designated advocate ... Term Care Insurance member benefit. , “I am very ...
Breaking Medicine News(10 mins):Health News:The Tuscany on Grace Bay Celebrates Providenciales Airport Expansion With Summer Specials to Travelers! 2Health News:Seeonic’s Industry Leading Technology Powers Interstate Batteries to Winning Award 2Health News:Coalition Presents Resiliency Training to Raise Awareness during Month of the Military Child (#MOTMC2015) 2Health News:Internationally Recognized British Indie Rock Outfit The 1975 Partner with Cadence & Cause to Provide Clean Drinking Water to Those in Need 2
... In response to ... In Health (PIH) Stand with Haiti initiative. Buildium started the campaign with a $1,000 donation, ... ... ongoing needs in Haiti, Buildium today announced a fundraising campaign to benefit the Partners In ...
... , ... ... ... ...
... , ... ... , ... , , ...
... deal with physical pain, researchers say , THURSDAY, Feb. ... back pain may find relief through cognitive behavioral therapy, ... beliefs. , Chronic lower back pain is one of ... the British researchers report. And, it can be expensive ...
... , ... ... , , , ... ...
... drugs intended to halt growth of brain cancer stem cells ... conclude that blocking these cells may be somewhat effective, but ... the job done. One focus of attack is a ... shown is important for cancer stem cell growth. A new ...
Cached Medicine News:Health News:Buildium Announces Fundraising Campaign to Benefit Haiti Relief Efforts 2Health News:DNC Chairman Tim Kaine Applauds President, Members of Congress on Today's Bipartisan Summit 2Health News:DNC Chairman Tim Kaine Applauds President, Members of Congress on Today's Bipartisan Summit 3Health News:Clinton Bush Haiti Fund Awards International Medical Corps $500,000 for Emergency Medical Care and Long-Term Rebuilding 2Health News:Clinton Bush Haiti Fund Awards International Medical Corps $500,000 for Emergency Medical Care and Long-Term Rebuilding 3Health News:Chronic Back Pain Soothed by Cognitive Behavioral Therapy 2Health News:Chronic Back Pain Soothed by Cognitive Behavioral Therapy 3Health News:NSBA Implores Congress to Act on Health Care Reform 2Health News:NSBA Implores Congress to Act on Health Care Reform 3Health News:Notch-blocking drugs kill brain cancer stem cells, yet multiple therapies may be needed 2
... D kit is an enzymeimmunoassay for the ... metabolites in serum or plasma. Calibrators, controls ... 25-OH D. The diluted samples are incubated ... a highly specific sheep 25-OH D antibody ...
... is the principal hormone responsible for the control ... the b-cells of the islets of Langerhans as ... C-peptide and insulin. Both are secreted in ... mature insulin molecule is comprised of two polypeptide ...
... Retinol binding Proetin (RBP) is small ... a complex with pre-albumin in blood but ... has been deliverd to the target cells. ... at the glomerulus and catabolized in the,renal ...
... The Immunoscan MPO-ANCA Kit is an ... vitro detection in human serum of the ... against myeloperoxidase to be used as an ... are a family of autoantibodies associated with ...
Medicine Products: